The Hay Fever Vaccine London 2026: The Complete Guide to Allergen Immunotherapy
Medically reviewed by The Online GP by The Wellness clinical team | Last updated: April 2026
The hay fever vaccine in the UK refers to allergen immunotherapy, a doctor-led treatment that retrains the immune system to tolerate pollen, dust mite, or pet allergens over a three-year course. Unlike antihistamines, which only mask symptoms, the hay fever vaccine treats the underlying cause and produces lasting relief that often continues for years after the course finishes. At The Online GP by The Wellness in Marylebone, allergen immunotherapy starts with a £150 specialist consultation followed by tailored treatment using MHRA-licensed sublingual tablets (Grazax, Acarizax, or Itulazax) or subcutaneous injections.
This guide explains exactly how the hay fever vaccine works, who it suits, what it costs in London, why three NICE approvals in the past 18 months have transformed access, and why it is the only hay fever treatment proven to modify the disease itself.
Speak to a GMC-registered doctor today: WhatsApp +44 7961 280835 | Email team@thewellnesslondon.com | Call 020 3951 3429
What is the hay fever vaccine?
The hay fever vaccine is allergen immunotherapy (AIT), a prescription-only medical treatment that gradually exposes the immune system to small, controlled doses of the allergen causing your symptoms. Over three years of daily use, this trains your body to tolerate pollen, dust mite, or other allergens rather than reacting to them. It is the only hay fever treatment classified as disease-modifying by the European Academy of Allergy and Clinical Immunology (EAACI) and the British Society for Allergy and Clinical Immunology (BSACI).
There are two delivery methods. Sublingual immunotherapy (SLIT) uses a tablet that dissolves under the tongue once daily, taken at home after the first supervised dose. Subcutaneous immunotherapy (SCIT) involves a series of injections given in clinic. SLIT has become the first-line approach in the UK because of its safety profile and convenience. Around 16 million people in the UK have hay fever, and approximately 1 in 4 has symptoms severe enough that standard antihistamines and nasal sprays do not provide adequate control. For this group, allergen immunotherapy is the next clinically appropriate step.
The treatment was developed in 1911 by Leonard Noon at St Mary's Hospital, London, making the UK the birthplace of allergen immunotherapy. More than a century of research, including landmark studies at Imperial College London and King's College London, has established it as the only intervention that produces sustained, long-term improvement.
How does the hay fever vaccine work?
The hay fever vaccine works by inducing immune tolerance: a process where your body learns to recognise the allergen as harmless rather than triggering the inflammatory cascade responsible for sneezing, congestion, itchy eyes, and post-nasal drip. Daily exposure to a precisely measured dose shifts the immune response from allergy-driving Th2 cytokines and IgE antibodies toward regulatory T cells and protective IgG4 antibodies.
The clinical mechanism unfolds in three phases. In the induction phase (weeks 1 to 8), the immune system begins recognising the allergen without reacting. In the maintenance phase (months 3 to 36), tolerance deepens as regulatory pathways take over. After the completion phase (year 3 onwards), most patients experience sustained relief without ongoing treatment, sometimes for decades. A 2017 study published in JAMA following patients three years after stopping a grass pollen SLIT course showed sustained reduction in symptoms compared with placebo.
This is fundamentally different from how antihistamines or steroid sprays work. Those medications block or suppress the inflammatory response while you are taking them. Allergen immunotherapy retrains the immune system itself, which is why effects persist long after the course ends.
Want to find out if immunotherapy is right for you? Request a same-day specialist consultation via WhatsApp or email team@thewellnesslondon.com
Which hay fever vaccines are licensed in the UK?
Three sublingual hay fever vaccines are MHRA-licensed in the UK in 2026, each targeting a specific allergen, alongside subcutaneous immunotherapy options for selected patients. All three SLIT tablets are now NICE-recommended for NHS use, though private access remains substantially faster.
Grazax (Phleum pratense, 75,000 SQ-T) is licensed for grass pollen allergic rhinitis in adults and children aged 5 and over. Manufactured by ALK-Abelló, it contains standardised Timothy grass pollen extract and provides cross-reactive coverage for most UK grass species. NICE Technology Appraisal TA246 supports its use for severe grass pollen rhinitis. Treatment starts 16 weeks before grass pollen season (so February for a June-July peak) and continues for three years.
Acarizax (12 SQ-HDM), also from ALK-Abelló, is licensed for house dust mite allergic rhinitis in adults aged 18 to 65 and adolescents aged 12 to 17, with persistent moderate to severe symptoms. NICE recommended Acarizax in January 2025 (TA1106). Unlike pollen treatments, it can be initiated at any time of year, and trials across more than 9,000 patients across 25 countries demonstrate consistent symptom reduction and reduced need for daily antihistamines.
Itulazax (12 SQ-Bet) is the newest addition, licensed for silver birch tree pollen allergic rhinoconjunctivitis in adults aged 18 and over. NICE recommended Itulazax in July 2025 (TA1066), making it the first NHS-approved tree pollen immunotherapy and potentially benefiting around 27,000 people in England with severe birch pollen allergy. It also provides cross-reactive coverage for alder and hazel pollen, the major early-spring tree allergens.
Subcutaneous immunotherapy (SCIT) and unlicensed allergen drops (such as Oraltek) are also available privately for allergens not covered by the three licensed tablets, including pet dander, mould, and weed pollen.
How much does the hay fever vaccine cost in London?
At The Online GP by The Wellness, the complete three-year hay fever vaccine pathway typically costs between £4,500 and £5,500, comparable to other premium London allergy clinics on Harley Street and substantially less than the cost of unmanaged severe hay fever over a working lifetime. Pricing is transparent and broken down by stage so you only pay for what you need.
Hay Fever Specialist Consultation (in-person at Marylebone or video): £150 for a 30-minute appointment with a GMC-registered doctor experienced in allergic rhinitis. Includes detailed history, examination, and treatment plan.
Allergy Testing (where required to identify or confirm triggers):
Specific IgE Hay Fever Profile (grass, tree, weed, dust mite): £295
Comprehensive Inhalant Allergy Panel (16 allergens including pets, mould): £395
ALEX³ Molecular Allergy Test (300+ allergen components): £495
Immunotherapy Initiation Appointment: £395 for the first supervised dose with 30-minute observation, written treatment plan, and aftercare guidance.
Ongoing Medication and Care: £125 to £150 per month for the SLIT tablet, plus 6-monthly review consultations included in the package. The medication itself is dispensed via private prescription from a UK pharmacy.
For comparison, doing nothing has a real cost too. UK research published in Clinical and Translational Allergy estimated severe hay fever causes individual productivity losses of £600 to £1,200 per pollen season through reduced work output, missed days, and impaired sleep, with cumulative impact running into tens of thousands over a working life.
Get a personalised pricing quote: WhatsApp +44 7961 280835 | Email team@thewellnesslondon.com
How do I know if the hay fever vaccine is right for me?
You are likely to be a candidate for allergen immunotherapy if you meet four criteria: confirmed allergic rhinitis lasting at least two pollen seasons, moderate to severe symptoms despite optimal use of antihistamines and intranasal steroids, a positive allergy test (specific IgE blood test or skin prick test) for an allergen with a licensed immunotherapy product, and no contraindicating health condition.
You are not a suitable candidate if you have uncontrolled or severe asthma, are pregnant (you can continue if already established before pregnancy after specialist review), have an active malignancy, are taking systemic immunosuppressive therapy, or have severe oral or dental disease that would prevent sublingual administration. Beta-blocker use also requires careful specialist assessment.
The decision is rarely straightforward without testing. Around 30 percent of people who self-identify as having "hay fever" actually have non-allergic rhinitis (vasomotor rhinitis or local allergic rhinitis), which does not respond to immunotherapy. Another 25 percent have multiple sensitivities where targeted single-allergen immunotherapy may be less effective than combined symptom optimisation. This is why a structured diagnostic pathway, beginning with a comprehensive specialist consultation, is essential before starting a three-year treatment commitment.
At The Wellness, every patient considering immunotherapy receives a structured assessment combining detailed history, validated questionnaires (such as the Total Nasal Symptom Score and the Rhinoconjunctivitis Quality of Life Questionnaire), and laboratory-confirmed allergy testing before any treatment recommendation.
What is the timeline of the hay fever vaccine?
The hay fever vaccine is a three-year commitment, but the timeline begins long before the first dose. Understanding when to start matters enormously: starting too late in the year produces minimal benefit during that pollen season, while starting too early extends costs unnecessarily. The optimal start window depends on which allergen you are treating.
For grass pollen (Grazax), start treatment at least 16 weeks before the grass pollen season begins. In the UK, grass pollen rises from early May, peaks in June and July, and tails off in August. The optimal start window is February to early March. Patients who start in March experience meaningful symptom reduction in the same season; those who start in May see partial benefit only.
For birch tree pollen (Itulazax), start at least 16 weeks before the birch pollen season. Birch pollen peaks in April and May in the UK, with alder and hazel pollens (which Itulazax also covers via cross-reactivity) starting from late January. The optimal start window is late autumn through early January.
For house dust mite (Acarizax), there is no seasonal restriction. Treatment can be initiated year-round because indoor dust mite levels are constant. Many patients start in autumn or winter when symptoms tend to peak due to increased indoor heating.
The first dose of any sublingual immunotherapy must be supervised by a doctor with a 30-minute observation period, after which subsequent daily doses are taken at home. Reviews follow at 1 month, 3 months, then every 6 months for the duration of the three-year course.
Start your treatment plan today: Book a specialist consultation via WhatsApp
What does the hay fever vaccine consultation involve?
A hay fever vaccine consultation at The Online GP by The Wellness is a 30-minute structured appointment with a GMC-registered doctor. It is designed to confirm your diagnosis, identify your specific allergens, rule out conditions that would contraindicate immunotherapy, and produce a written treatment plan you can take away the same day.
Your consultation includes a detailed allergy history covering symptom pattern, seasonal timing, triggers, medication response, and impact on sleep, work, and daily life. The doctor performs a focused examination of nose, throat, and chest, including evaluation for nasal polyps and signs of co-existing asthma. A medication review identifies whether your current treatment has been used at maximum licensed doses, with optimal technique, and for sufficient duration.
If allergy testing has not already been performed, we recommend the most appropriate diagnostic test based on your history. Specific IgE blood testing is suitable for most patients and does not require stopping antihistamines. Skin prick testing provides immediate results in 20 minutes but requires antihistamine cessation 72 hours beforehand. ALEX³ molecular allergy testing is reserved for complex cases, multiple sensitivities, or where conventional results do not fit the clinical picture.
You leave the consultation with a clear written plan, recommended timing, full pricing breakdown, and direct contact with your treating doctor. There is no obligation to proceed: many patients use the consultation to optimise their existing treatment first and return for immunotherapy in subsequent seasons.
Is the hay fever vaccine safer than the Kenalog injection?
Yes, by a substantial margin, and the comparison is worth understanding because confusion between these two treatments is widespread. They are fundamentally different drugs with different mechanisms, different licensing status, and different safety profiles.
Kenalog (triamcinolone acetonide) is a long-acting corticosteroid injection. It is not a vaccine. It works by suppressing the entire immune system for several weeks, indirectly reducing allergic inflammation alongside many other immune functions. Kenalog is not licensed in the UK for hay fever, has been off-label for this indication since the NHS withdrew it from routine use, and was discontinued by its manufacturer Bristol-Myers Squibb in June 2025. The MHRA and the Committee of Advertising Practice (CAP) have taken regulatory action against clinics promoting Kenalog as a hay fever treatment because doing so misleads patients about its licensed use. Side effects include immune suppression with increased infection risk, mood changes, weight gain, sleep disturbance, raised blood pressure, and rare but serious complications including avascular necrosis and adrenal suppression.
Allergen immunotherapy (the actual hay fever vaccine) is MHRA-licensed, NICE-approved, and recommended by every major international allergy guideline including BSACI, EAACI, and AAAAI. Side effects are typically mild and confined to the mouth (oral itching in around 30 percent of users in the first month, usually settling spontaneously). Systemic reactions are rare with SLIT (under 1 in 1,000 doses). Crucially, immunotherapy treats the underlying allergic disease rather than suppressing immunity wholesale.
For severe hay fever, the modern evidence-based approach is to optimise prescription antihistamines and intranasal corticosteroids first, then move directly to allergen immunotherapy if symptoms remain inadequately controlled. The era of the steroid jab is over.
What results can I expect from the hay fever vaccine?
Realistic expectations matter for any three-year treatment. Across published clinical trials and real-world cohorts, allergen immunotherapy reduces symptom severity by 30 to 40 percent on average, reduces use of rescue medications (antihistamines, nasal sprays, eye drops) by approximately 30 percent, and improves quality of life scores meaningfully across sleep, productivity, and outdoor activity.
Around 80 to 87 percent of patients report a clinically meaningful improvement after a complete three-year course, with 30 to 40 percent reporting near-complete remission of symptoms. The remaining 13 to 20 percent of patients see partial benefit, and a small minority do not respond, which is why specialist assessment matters: response rates are higher when allergen identification is accurate and adherence is good.
The most distinctive feature of immunotherapy compared with daily medications is sustained benefit after treatment stops. Trials of grass pollen SLIT have demonstrated sustained symptom reduction at least 2 to 3 years after the three-year course ends. Real-world follow-up suggests benefits often persist for 7 to 12 years, and in some patients indefinitely. Cost per year of benefit is therefore substantially lower than the upfront price suggests.
Benefits extend beyond hay fever symptoms. Multiple studies (including a key 2018 paper in the Journal of Allergy and Clinical Immunology) suggest that childhood allergen immunotherapy reduces the risk of progressing from allergic rhinitis to asthma. For adults, controlling rhinitis often improves co-existing asthma symptoms and reduces inhaler use.
Speak to a doctor about expected outcomes for your specific situation: WhatsApp +44 7961 280835
Why choose The Wellness for the hay fever vaccine in London?
The Online GP by The Wellness offers a deliberately premium pathway for allergen immunotherapy designed around three principles: medical accuracy, accessibility, and continuity of care. Our Marylebone clinic at 10 Portman Square sits two minutes from Baker Street, immediately adjacent to Harley Street, with full diagnostic facilities under one roof.
GMC-registered doctors with experience in allergic rhinitis and immunotherapy lead every consultation. There are no algorithm-led online questionnaires substituting for clinical judgement, which BSACI guidelines explicitly warn against for immunotherapy initiation.
Same-day and next-day appointments are standard. NHS specialist allergy clinics typically have waiting times of 6 to 12 months. Private clinics on Harley Street often have 2-to-4 week waits for new patients. The Wellness sees most new patients within 24 to 72 hours.
MHRA-compliant care. We do not offer Kenalog or any unlicensed off-label hay fever injection. Every treatment we offer is licensed, evidence-based, and aligned with NICE and BSACI guidelines. This matters for patient safety and for the integrity of your medical record if you have private health insurance, occupational health needs, or international travel requirements.
Multilingual doctors including English, Arabic, Spanish, French, and Dutch speakers, supporting our substantial international patient base.
Integrated diagnostic capability: blood tests, skin prick testing, and access to ALEX³ molecular allergy testing all delivered from the same Marylebone location, with results typically within 24 to 48 hours.
Continuity through your three-year course: the doctor who initiates your treatment remains your point of contact for the duration, with 6-monthly reviews built into the standard care package.
Frequently asked questions
Is allergen immunotherapy painful?
Sublingual immunotherapy (Grazax, Acarizax, Itulazax) is not painful. The tablet dissolves under the tongue in about 1 minute. Around 30 percent of patients experience mild oral itching or tingling in the first 1 to 4 weeks of treatment, which usually settles spontaneously. Subcutaneous immunotherapy (allergy injections) involves a small needle in the upper arm, comparable to a flu jab, with very minor stinging.
Will my private health insurance cover the hay fever vaccine?
Coverage varies significantly between insurers. Most UK private medical insurance policies exclude chronic allergy management, including ongoing immunotherapy medication. However, many policies do cover diagnostic consultations and allergy testing. Bring your insurance details to your initial consultation and our team will help you understand exactly what is covered. We provide itemised invoices for all services to support your claims.
Can I take antihistamines while having the hay fever vaccine?
Yes. Antihistamines and intranasal corticosteroids can be used alongside allergen immunotherapy and are often recommended in the first season of treatment as your immune tolerance builds. Some specialists actually recommend taking an antihistamine 30 to 60 minutes before each SLIT dose during the first month to reduce oral itching. Your doctor will advise on the right combination for you.
What happens if I miss doses?
Missing one or two doses occasionally has no significant impact. Missing more than 7 consecutive days requires a phone consultation before resuming, as the dose may need to be temporarily reduced or restarted under supervision depending on duration of interruption. We provide direct WhatsApp access to your treating clinician for these situations.
Can children have the hay fever vaccine?
Yes. Grazax is licensed from age 5, and Itulazax and Acarizax from age 12 (Acarizax) or 18 (Itulazax) for adolescents and adults. Allergen immunotherapy in children has additional benefits including potentially preventing progression from allergic rhinitis to asthma. Paediatric assessment requires specialist input and may be referred to colleagues in paediatric allergy.
How is the hay fever vaccine different from a flu vaccine?
A flu vaccine introduces inactivated virus components to teach your immune system to recognise and attack future flu infections, with protection lasting one season. Allergen immunotherapy gradually increases exposure to a substance your immune system already recognises but reacts to inappropriately, retraining it over three years to tolerate that substance. Both are correctly described as vaccines in their respective scientific senses, even though they work through different mechanisms.
What if I move countries during my three-year course?
Allergen immunotherapy is a globally recognised treatment available in most developed healthcare systems. We provide full medical records and treatment plans on request to support continuity with overseas providers. Many of our patients are international professionals who continue treatment between London and other cities including Dubai, Geneva, New York, and Singapore.
Book your hay fever vaccine consultation today
The 2026 pollen season has already begun, with alder and hazel counts climbing across southern England since late February. Grass pollen, the dominant trigger for around 90 percent of UK hay fever sufferers, peaks from early June. The window to start treatment for benefit this season is closing.
The Online GP by The Wellness offers same-day and next-day specialist hay fever consultations at our Marylebone clinic and via secure video. Every patient receives a structured assessment, transparent pricing, written treatment plan, and direct access to a GMC-registered doctor for the duration of care.
Three ways to book today:
WhatsApp: Message +44 7961 280835 for a same-day reply from our medical team.
Email: team@thewellnesslondon.com for detailed enquiries or insurance pre-authorisation.
Phone: 020 3951 3429 to speak directly to our team during clinic hours.
The Wellness, 10 Portman Square, Marylebone, London W1H 6AZ. GMC-registered doctors. Same-day appointments. MHRA-compliant care. The actual hay fever vaccine, prescribed properly.
References and further reading
NICE Technology Appraisal TA1066 (Itulazax for severe birch pollen allergic rhinitis), July 2025. Available at nice.org.uk
NICE Technology Appraisal TA1106 (Acarizax for moderate to severe house dust mite allergic rhinitis), 2025. Available at nice.org.uk
NICE Technology Appraisal TA246 (Grass pollen allergen extract for grass pollen-induced rhinitis), 2012, currently under review
BSACI Guidelines for the Diagnosis and Management of Allergic and Non-Allergic Rhinitis. British Society for Allergy and Clinical Immunology, latest revision.
Durham SR et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification two years after 3 years of treatment. Allergy, 2017.
EAACI Guidelines on Allergen Immunotherapy: Allergic Rhinoconjunctivitis. European Academy of Allergy and Clinical Immunology.
NHS guidance on hay fever (allergic rhinitis), nhs.uk
MHRA and CAP regulatory action on Kenalog advertising for hay fever, gov.uk
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Allergen immunotherapy is a prescription-only treatment that requires individual medical assessment. Always consult a qualified healthcare provider for diagnosis and treatment. The Wellness is a CQC-registered private healthcare clinic with GMC-registered doctors.
